OptiNose, Inc. (OPTN) Analysts See $-0.74 EPS on June, 12

May 17, 2018 - By Brian Ramirez

Investors expect OptiNose, Inc. (NASDAQ:OPTN)’s quarterly earnings on June, 12., as reported by RTT. Wall Street sees 15.63 % negative EPS growth as of June, 12. Ticker’s shares touched $24.58 during the last trading session after 4.51% change.OptiNose, Inc. is after having 0.00% since May 17, 2017. OPTN has 597,935 volume or 618.64% up from normal. The stock underperformed the S&P 500 by 11.55%.

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States.The firm is worth $931.81 million. The company's lead product includes XHANCE, a therapeutic product utilizing its proprietary breath powered exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.Last it reported negative earnings. It also markets AVP-825 for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc.

For more OptiNose, Inc. (NASDAQ:OPTN) news brought out recently go to: Nasdaq.com, Benzinga.com, Nasdaq.com, Nasdaq.com or Digitaljournal.com. The titles are as follows: “Optinose CEO Peter Miller and President/COO Ramy Mahmoud Named EY Entrepreneur of the Year 2018 Finalists in …” brought out on April 23, 2018, “Benzinga’s Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings” on May 16, 2018, “Optinose Reports First Quarter 2018 Financial Results and Recent Operational Highlights” with a publish date: May 14, 2018, “Optinose to Report First Quarter 2018 Financial Results and Corporate Updates on May 14, 2018” and the last “OptiNose, Inc. to Host Earnings Call” with publication date: May 14, 2018.

OptiNose, Inc. (NASDAQ:OPTN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.